Role of ETB receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788  by Brunner, Friedrich & Doherty, Annette M.
FEBS Letters 396 (1996) 238 242 FEBS 17709 
Role of ETB receptors in local clearance of endothelin-1 in rat heart" 
studies with the antagonists PD 155080 and BQ-788 
Friedrich Brunner a,*, Annette M. Doherty b
~Institut fiir Pharmakologie und Toxikologie, Karl-F'ranzens-Universitgit Graz, Universitiitsplatz 2, A-8010 Graz, Austria 
bDepartment of Chemistry, Parke Davis Pharmaceutical Research, Ann Arbor, M1 48105, USA 
Received 16 August 1996; revised version received 24 September 1996 
Abstract The effects of two endothelin (ET) receptor antago- 
nists, PD 155080 (ETA selective) and BQ-788 (ETB selective), on 
cardiac function and ET-1 release were studied in isolated rat 
hearts. In normoxic hearts, infusion of PD 155080 (50 nM-5 
oM) reduced coronary resistance, but had no effect on ET-1 
release. Low concentrations of BQ-788 (2 and 20 nM) had no 
effect on coronary resistance; high concentrations (0.2 and 2 
gM) increased it ,-.2-fold; all concentrations increased ET-1 
release (up to 24-fold). Similar results were obtained in 
reperfused hearts. Although concentrations of ET-1 were higher 
in interstitial fluid than coronary effluent, levels never exceeded 
the low pg/ml range. These results indicate that (1) ETA 
receptors mediate coronary constriction, whereas ETB receptors 
bind and sequester ET-1, and (2) ET-1 displaced by ETB 
antagonist accesses ETA receptors resulting in coronary 
constriction. 
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1. Introduction 
Endothelin-1 (ET-1), originally isolated from the condi- 
t ioned medium of cultured vascular endothelial cells [1], is a 
polypeptide with numerous biological actions in vitro and in 
vivo. In vascular beds, ET-1 modulates coronary resistance by 
stimulating the release of endothelial relaxing factors or by 
constricting smooth muscle cells [2,3]. Whether endogenous 
ET-1 is a vasodi lator or vasoconstr ictor may depend on the 
concentrat ion of ET-1 at vascular ET receptors, the density of 
receptor subtypes, the efficacy of receptor-effector coupling, 
and the turnover of receptors. One of us has previously de- 
termined interstitial ET-1 levels in rat hearts and found that 
interstitial ET-1 levels only reached the pg/ml, i.e. the vasodi- 
lator range and that cardiac ET-1 seemed to be involved in 
lowering vascular tone rather than increasing it [4]. In con- 
trast, in the human forearm antagonism of ETA receptors by 
BQ-123 caused vasodi latation [5], indicating that ET-1 is a net 
vasoconstr ictor in forearm resistance vessels. 
Infusion of dual ETA/ETB receptor antagonists into experi- 
mental animals increased plasma ET-1 levels manifold [6,7], 
possibly by displacing ET-1 bound to tissue ETB receptors [8]. 
These in vivo data, together with preliminary ET-1 effiux 
measurements in rat hearts [9], raise the possibility of a local 
clearance mechanism mediated by ETB receptors. We hy- 
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pothesized that cardiac ETA receptors mediate hemodynamic 
effects, and ETB receptors clearance, or clearance and vascu- 
lar, effects. Hearts were perfused with a colloid-free perfusion 
medium to generate interstitial fluid [4], and the effect of PD 
155080, a ETA receptor-selective antagonist [10], or BQ-788, a 
ETB receptor antagonist [11], on myocardial, vascular, and 
electrical function as well as the rate of ET-1 secretion into 
coronary effluent (luminal release) and interstitial fluid (ab- 
luminal release) were monitored under normoxic, ischemic, 
and reperfusion conditions. 
2. Materials and methods 
2.1. Materials 
PD 155080 (2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl)- 
4-oxobut-2-enoate×Na), BQ-788 (N-cis-2,6-dimethyl-piperidinocar- 
bonyl- L-y-methylleucyl- D- 1 - methoxycarbonyltryptophanyl- D-norleu- 
cineX Na (= PD 160900-0015) and PD 142893 (Ac-D-3,3-diphenylala- 
nine-k-Leu-k-Asp-L-Ile-L-lle-L-TrpX2Na) were synthesized at Parke- 
Davis Pharmaceutical Research, Ann Arbor, MI, USA. All other 
materials were described previously [4,9]. 
2.2. Heart perfusions 
Rat hearts were perfused in an upside-down position via the aorta 
at 9 ml/min per g heart wet weight. Interstitial fluid (transudate) 
produced by ventricles and appearing on their surface was collected 
under a latex cap using slight suction and was sampled in exchange- 
able vials [4]. Transudate flow slowly increased from an initial 50 + 1 
gl/min (45 rain, end of equilibration period) to 128+ 3 gl/min after 
255 min. ET-1 was determined in timed collections of coronary efflu- 
ent and transudate and expressed as concentration (pg/ml). Func- 
tional parameters were monitored throughout he experiment and 
included heart rate, left ventricular developed pressure (LVDevP; a 
measure of systolic function), left ventricular end-diastolic pressure 
(LVEDP; a measure of diastolic function), coronary perfusion pres- 
sure (CPP; a measure of coronary resistance), and the incidence of 
ventricular extrasystoles (VES) [4,12]. 
2.3. Experimental protocols 
(1) Normoxic perfusions. Hearts were equilibrated (45 min) and 
perfused for 210 min (total duration: 255 min) in the presence of 
vehicle, PD 155080 (50 nM), or BQ-788 (2 nM). For concentration- 
effect studies, the antagonists (PD 155080:500 nM and 5 gM; BQ- 
788: 20, 200, 2000 nM) were tested cumulatively, starting at 45 rain 
and allowing 15 min for each concentration, at the end of which CPP 
was determined (total duration: 75 min (PD 155080) or 90 min (BQ- 
788)). Because CPP was unchanged up to ~90 min after vehicle 
(Table 1), the CPP values so measured reflect the net effect of the 
antagonists. 
(2) Ischemia/reperfusion. After equilibration (baseline), the protocol 
comprised a control (60 rain), ischemic (60 min), and reperfusion 
period (30 min) (total duration: 195 min). Ischemia was generated 
by reducing coronary flow to 1 ml/min. PD 155080 (50, 500, and 
5000 nM) and BQ-788 (2, 20, and 200 nM) were added to the perfu- 
sion medium during all three phases. 
2.4. Determination of ET-1 
The peptide was concentrated by solid-phase xtraction followed by 
quantitative radioimmunoassay (RIA) as described previously [4]. 
All rights reserved. 
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Briefly, coronary effluents and interstitial transudates were chromato- 
graphed on C2 cartridges, ET-I was eluted with acetonitrile (70%), 
dried, and reconstituted for RIA using a commercial antibody (Pe- 
ninsula Laboratories, Belmont, CA, USA). The cross-reactivity of
other ET isomers and big ET-1 in this assay was < 5% and < 37%, 
respectively, according to the supplier. No big ET-I was detected in 
effluents or transudates in separate xperiments using an antibody 
specific for big ET-I [13]. 
2.5. Statistics 
Group data are given as mean values_+ S.E.M. (n, number of 
hearts). Data were subjected to two-way analysis of variance for re- 
peated measurements to account for different treatments (control, 
ischemia, reperfusion) and factors (vehicle, antagonists), followed by 
the Scheff~ test to compare single means. A P value <0.05 was 
considered significant. 
3. Results 
The basic hemodynamic parameters of the preparation 
using oxygenated perfusion medium and the effects of ET 
receptor antagonists are listed in Tables 1 and 2. As expected 
at constant flow perfusion, LVDevP was stable for several 
hours and CPP slowly increased with time (P < 0.05 vs base- 
line). Heart rate and diastolic function (LVEDP) remained 
stable (not shown). Neither PD 155080 (50 nM) nor BQ-788 
(2 nM) affected systolic function (LVDevP). The rise in cor- 
onary resistance (CPP) observed for vehicle was completely 
antagonized by PD 155080 (50 nM); a similar inhibition 
was observed at higher concentrations (0.5 and 5 ~tM, n =4;  
not shown). In the presence of BQ-788, CPP initially (2 and 
20 nM) was unaffected, but increased above vehicle values at 
higher concentrations (0.2 and 2 laM; Tables 1 and 2). Basal 
rate of ET-1 secretion was 0.27_+0.01 pg/min (effluent) and 
0.005 + 0.001 pg/min (transudate), resulting in similar concen- 
trations in effluents and transudates (less than ~0.1 pg/ml; 
Figs. 1 and 2). PD 155080 (50 nM) was without effect on ET-1 
levels in effluent and transudate; higher concentrations (0.5 
and 5 ~tM) were equally ineffective (n=4, not shown). BQ- 
788 (2 nM) caused a continuous increase in ET-1 concentra- 
tion, whose dose dependence is shown in Table 2. The maxi- 
mally active concentration (,~ 2 laM) increased ET-1 ~ 8-fold 
(effluent) and ~24-fo ld (transudate). 
The hemodynamic parameters measured for the ischemia/ 
reperfusion model are listed in Tables 3 and 4. Expectedly, 
low-flow perfusion resulted in global ischemia and greatly 
impaired cardiac function (not shown). After restoration of 
normal coronary flow, cardiac function recovered incomple- 
tely as expected. PD 155080 (50 nM) improved reperfusion 
systolic (LVDevP) and diastolic (LVEDP) function and com- 
pletely prevented the ischemia-induced increase in CPP. High- 
er concentrations (0.5 and 5 laM) were similarly effective 
(n =4, not shown). The lowest concentration of BQ-788 (2 
nM) did not affect cardiac function during the control, is- 
chemic, and reperfusion periods (Table 3), a 10 times higher 
concentration appeared to reduce CPP (P=0.055), and the 
highest concentration tested (200 nM) considerably increased 
CPP (Table 4). The effects on ET-1 secretion into coronary 
effluent in the ischemia/reperfusion model are shown in Fig. 3. 
Antagonism of ETA receptors with PD 155080 (50 nM) had 
no effect (P > 0.05 vs vehicle), but antagonism of ET~ recep- 
tors with BQ-788 (2 200 nM) increased ET-1 secretion in all 
three phases (for clarity, data for ischemia not shown). 
The effects of ET receptor antagonists on reperfusion VES, 
a common phenomenon in experimental ischemia/reperfusion 
and in ischemic syndromes in humans, are shown in Fig. 4. 
PD 155080 (50 nM) and the mixed ETA/ETB receptor antago- 
nist PD 142893 were similarly effective (74 and 81% reduction, 
P > 0.05), whereas BQ-788 was ineffective at 2 nM, protective 
at 20 nM (56% reduction), and deleterious at 200 nM (1.5-fold 
increase). The drugs had similar effects in early and late re- 
perfusion. The protective ffect of 20 nM BQ-788 was abol- 
Table 1 
Effect of PD 155080 (ETA receptor antagonist, 50 nM) and BQ-788 
under normoxic onditions 
(ETB receptor antagonist, 2 nM) on left ventricular and coronary function 
Time (min post mounting) Vehicle PD 155080 BQ-788 
LVDevP (mm Hg) CPP (mm Hg) LVDevP (mm Hg) CPP (mm Hg) LVDevP (mm Hg) CPP (mm Hg) 
45 87_+4 53_+2 84_+ 1 53_+2 87+2 51 +2 
75 82-+4 57-+2 83-+2 54+3 87+2 55_+3 
105 80_+3 59_+ 1 84_+2 55+3 84+2 58_+2 
135 83_+2 63+3 84-+2 55+3 84+2 62+ 1 
165 87-+3 68+3 84_+2 55+2* 82+2 68+ 1 
195 85_+ 1 73+3 82_+2 55+2* 79_+2 74+2 
225 82 _+ 2 78 _+ 8 82 _+ 2 57 + 3* 79 _+ 2 79 _+ 1 
255 77_+2 83_+8 81 _+2 58_+3* 78_+ 1 82_+ 1 
Data are mean values+ S.E.M., n = 6. Heart rate was 300 + 17 beats/min (baseline) and was not affected by antagonists (P> 0.05). *Significantly 
different from vehicle. The differences vs. baseline (45 min) are not indicated separately. 
Table 2 
Concentration dependence of BQ-788 effects on coronary perfusion pressure and ET-1 release in coronary effluent and interstitial transudate 
BQ-788 concentration ( M) CPP (mm Hg) ET-1 level in 
Effluent (pg/ml) Transudate (pg/ml) 
Vehicle 50 + 1 0.03 + 0.001 0.10 _+ 0.013 
2 51 _+ 1 0.04_+0.001" 0.15_+0.006" 
20 55 _+ 2 0.04 _+ 0.001" 0.16 _+ 0.015* 
200 96 + 1 * 0.23 _+ 0.004* 2.4 _+ 0.17" 
2000 100 _+ 2* 0.25 _+ 0.001 * 2.3 + 0.18* 
The antagonist was added cumulatively, starting after equilibration (45 min), allowing 15 min for each concentration. Data are mean 
values _+ S.E.M., n = 5. *Significantly different from vehicle. 
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Fig. 1. Effects of PD 155080 (50 nM) and BQ-788 (2 nM) on basal 
ET-1 secretion into coronary effluent of isolated rat hearts at nor- 
moxic conditions• The antagonists were added after collection of the 
baseline sample (45 rain). Mean values_+ S.E.M., n = 6. *Significantly 
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Fig. 2. Effects of PD 155080 (50 nM) and BQ-788 (2 nM) on basal 
ET-1 secretion into interstitial transudate of isolated rat hearts at 
normoxic onditions. The antagonists were added after collection of 
the baseline sample (45 min). Mean values _+ S.E.M., n=6. *Sig- 
nificantly different from vehicle (P < 0.05). 
ished by concomitant infusion of indomethacin (10 gM) so 
that both the incidence of VES (167+ 15) and CPP (100+5 
mm Hg) were restored to vehicle level (n- -3;  data not shown). 
4. Discussion 
This study shows that the ETA receptor subtype mediates 
myocardial and coronary effects of endogenous ET-1, whereas 
the ETB subtype appears to bind and sequester ET-1 without 
mediating hemodynamic effects in a rat heart model. Because 
BQ-788 increased ET-1 release from the heart in a time- and 
concentrat ion-dependent manner  without affecting CPP or 
myocardial function (at 2 and 20 nM;  Tables 1 and 2), this 
strongly indicates that cardiac ETB receptors are involved in 
the local sequestration and clearance of ET-1, both in nor- 
moxia and after ischemia/reperfusion. After 0.2 or 2 gM BQ- 
788, considerably more ET-1 was displaced than in the pres- 
ence of less antagonist,  resulting in measurable vasoconstric- 
tor effects (increase in CPP), presumably consequent to bind- 
ing and activation of ETA receptors. To avoid any binding to 
ETB receptors, a low concentrat ion of PD 155080 (50 nM) 
was initially chosen and later supplemented with higher con- 
centrations (500 and 5000 nM), all of which consistently in- 
hibited the t ime-dependent rise in CPP, both in normoxia and 
after ischemia, but were entirely ineffective at mobil izing ET-1 
into effluent or transudate. The much higher efficacy of PD 
155080 in this preparat ion than in rabbit  femoral and pul- 
monary artery (KB ~ 500-1500 nM) may be due to differences 
in tissues (microvascular bed vs. conduit arteries) and species, 
but is supported by binding data (ICs0 < 10 nM at the ETA 
receptor [10]). 
Previously, it was shown that the uptake of ET-1 into rat 
tissues in vivo results in its rapid clearance from the plasma by 
a ETB receptor-specific mechanism [8]. The present data ex- 
tend these observations and suggest hat ET-1, in addit ion to 
its removal by lung tissue, is also cleared locally in the heart 
and that, by implication, the removal process may generally 
involve ETB receptors. Hence, with respect to the increased 
plasma levels of ET-1 observed after infusion of subtype non- 
selective antagonists [6,7], the increase probably resulted from 
Table 3 
Effect of PD 155080 and BQ-788 on left ventricular and coronary function under normoxic (control) and reperfusion conditions 
Treatment Control (60 rain) Reperfusion 
3 min 30 min 
Vehicle 
LVDevP 88 -+ 3 61 _+ 2 65 + 3 
CPP 52 -+ 3 78 -+ 2 97 +- 6 
LVEDP 0 21 +2 13-+2 
PD 155080 (50 nM) 
LVDevP 84 + 2 66 -+ 3 78 _+ 2* 
CPP 54 + 2 54 _+ 4* 59 _+ 2* 
LVEDP 0 17_+2 7-+ I* 
BQ-788 (2 nM) 
LVDevP 84 _+ 2 58 _+ 2 65 -+ 1 
CPP 55-+2 80-+2 97_+3 
LVEDP 0 23_+3 13_+ 1 
All data are given in mm Hg. Data are mean values _+ S.E.M., n=6. Heart rate was 292+ 11 beats/min (baseline) and was not affected by 
antagonists (P > 0.05). *Significantly different from vehicle. The differences between treatments (reperfusion vs. control) were analyzed by analysis 
of variance as described in Section 2, but symbols are omitted for clarity. 
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Fig. 3. Effect of PD 155080 and BQ-788 on ET-1 secretion into cor- 
onary effluent under control and reperfusion (R) conditions (R-3: 
0 3 min; R-30:20-30 min). The antagonists were added to perfu- 
sate during the control, ischemic (not shown) and reperfusion 
phases. Mean values_+ S.E.M. of 6 hearts in each case. *Significantly 
different from vehicle (P < 0.05). The differences between treatments 
(reperfusion vs. control) were analyzed by analysis of variance as 
described in Section 2, but symbols are omitted for clarity. 
the interaction of these antagonists with ETB receptors in 
peripheral tissues, including the heart. 
In view of the constant rate of synthesis observed over 255 
min, the additional ET-1 appearing in transudate and effluent 
was in all likelihood peptide displaced from tissue receptors. A
continuous increase in ET-1 appearance (Figs. 1 and 2) is 
expected as a direct result of the binding reaction kinetics 
involving a very potent endogenous ligand pre-bound to re- 
ceptors (ET-1) and a much less avid antagonist. The relative 
concentrations of ET-1 in effluent and transudate also merit 
mention. Both were similar at baseline (Figs. 1 and 2), but 
transudate levels increased three times more after BQ-788 
than effluent levels (Table 2), suggesting that the pharmaco- 
dynamic effects of ETr~ receptor antagonism in this model 
appear to be determined mainly by the transudate (i.e. tissue) 
level of ET-1. Whether the same ETB receptors also mediate 
the coronary relaxation observed in rat hearts after infusion 
of exogenous ET-I [9] or else whether coronary ETB receptors 
may mediate dual, i.e. indirect vasodilator as well as vasocon- 
strictor effects as suggested for dog heart [14], is unclear and 
requires further work. 
Considerable vidence suggests that myocardial ischemic 
injury is modulated by ET-1 released uring ischemia or re- 
perfusion [15], but its pathophysiological effects are far from 
clear, in particular the effects of antagonists on post-ischemic 
function and infarct size are variable and appear to depend on 
the antagonist used. Thus, the mixed ETA/ETB receptor an- 
tagonist TAK-044 showed a limited inhibitory effect on the 
250 
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Fig. 4. Effect of PD 155080, BQ-788, and PD 142893 (mixed ETA/ 
ETB receptor antagonist) on the incidence of ventricular extrasys- 
toles (VES) during reperfusion. The antagonists were added to per- 
fusate during the control, ischemic (not shown) and reperfusion 
phases. Mean values _+ S.E.M. of 4 (vehicle) or 6 hearts. *Sig- 
nificantly different from vehicle (P < 0.05). The differences between 
treatments (reperfusion vs. control) were analyzed by analysis of 
variance as described in Section 2, but symbols are omitted for 
clarity. 
extension of infarct size in rats [16], whereas BQ-123 (ETA 
receptor antagonist) was without effect in the same model 
[17]. Another ETA receptor antagonist, FR 139317 was with- 
out effect in a rabbit model of ischemia/reperfusion [18], and 
led to an increase, rather than a decrease in infarct size in 
dogs [19]. Our results may be of relevance to these discrepan- 
cies. Thus, an antagonist may be expected either to antagonize 
endogenous ET-1 despite mobilization from inactive receptors 
(mixed ETA/ETB receptor antagonist), or to antagonize ETA 
receptor-mediated ffects without displacing inactive ET-1 
(ETA receptor antagonist), or to antagonize ETB receptor- 
mediated effects and to displace ET-1 from inactive receptors, 
followed by possible action on ETA receptors (ETB receptor 
antagonist). Naturally, the net antagonist effect will also de- 
pend on the antagonist concentration attained at the respec- 
tive subtypes. 
Previous evidence has implicated ETA receptors in the gen- 
esis of reperfusion arrhythmias in rats [20]. Here, the proar- 
rhythmic role of this subtype was confirmed and a role for the 
ETB receptor was excluded. Expectedly therefore, the subtype 
non-selective antagonist PD 142893 [21] showed a similar 
antiarrhythmic potency as the ETA selective antagonist PD 
155080 (Fig. 4). The receptor mediating the proarrhythmic 
effect of ET-I is probably localized on the myocardial cell 
and may be activated by ET-1 generated locally by cardio- 
Table 4 
Effect of BQ-788 on coronary perfusion pressure under normoxic and reperfusion conditions 
BQ-788 concentration Baseline (30 min) Control (60 min) Reperfusion 
3 min 30 min 
Vehicle 52 + 3 57 + 2 78 + 2 97 + 6 
2 nM 52_+3 55+2 80_+2 97-+3 
20 nM 51 -+3 52-+3 75+2 83-+3 
200 nM 51 -+3 104-+ 3" 115_+2" 136_+2" 
The antagonist was added during all three phases, one concentration per heart. Data (mm Hg) are mean values_+ S.E.M., n =4-6. *Significantly 
different from vehicle. 
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myocytes as a consequence of ischemia [22]. The lower proar- 
rhythmic potency of 20 nM than either 2 or 200 nM BQ-788 
was unexpected; because it was abolished by indomethacin, it 
is likely due to increased release of prostacyclin [23,24] stimu- 
lated by ET-1. At 200 nM BQ-788, the beneficial effect of the 
prostanoid turns into an overall deleterious effect due to the 
severalfold higher ET-I level (Fig. 3). 
In conclusion, a ETA receptor antagonist was cardioprotec- 
tive whereas an antagonist of ETB receptors caused increased 
coronary and interstitial levels of ET- 1 resulting in heightened 
coronary constrictor effects. These results are relevant o the 
potential therapeutic role of ET receptor antagonists in dis- 
eases associated with acute vasoconstriction or vasospasm, 
including coronary vasospasm [25] and myocardial infarction 
[26]. A mixed ETA/ETB receptor antagonist was recently 
shown to increase the circulating plasma level of endogenous 
ET-1 in humans some 10-fold [27], indicating that displace- 
ment from ETB receptors occurs in humans as well and that 
this phenomenon is likely to be of clinical importance. 
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